5-Bromo-2-isobutoxypyrimidine

Catalog No.: 
ACMURF112
CAS No.: 
1289041-19-5
Molecular Formula: 
C8H11BrN2O
Molecular Weight: 
231.09
5-Bromo-2-isobutoxypyrimidine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$286.00InquiryInquiry
100mg95%$427.00InquiryInquiry
250mg95%$718.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-Bromo-2-isobutoxypyrimidine
IUPAC Name5-bromo-2-isobutoxypyrimidine
Molecular FormulaC8H11BrN2O
Molecular Weight231.09
SMILESCC(C)COC1=NC=C(Br)C=N1
InChI KeyMEIADTWPWWGKEP-UHFFFAOYSA-N
Synonym5-Bromo-2-isobutoxypyrimidine;5-Bromo-2-(2-methylpropoxy)pyrimidine
CAS No.1289041-19-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACMURF112 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACJMSY940 route compound structure diagram
    ACJMSY94032779-36-5In Stock
  4. Then
  5. ACMURF112 route product structure diagram
    ACMURF1121289041-19-5
Inquiry

2. ACMURF112 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACJMSY940 route compound structure diagram
    ACJMSY94032779-36-5In Stock
  4. Then
  5. ACMURF112 route product structure diagram
    ACMURF1121289041-19-5
Inquiry

3. ACMURF112 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACBHXW019 route compound structure diagram
    ACBHXW019214290-49-0In Stock
  4. Then
  5. ACMURF112 route product structure diagram
    ACMURF1121289041-19-5
Inquiry

Comments (0)